Anacor Pharmaceuticals announced that the first patient has been dosed in a Phase 2b trial of AN2728 for the treatment of psoriasis. This double-blind, randomized, vehicle-controlled trial plans to enroll 60 patients with mild to moderate plaque-type psoriasis who will be randomized to 2% AN2728 topical ointment or vehicle in a 2:1 ratio. Given its size, the trial is not designed to demonstrate statistical differentiation of AN2728 from vehicle, but to inform the size and design of the two planned pivotal Phase 3 trials for AN2728.
AN2728 is a boron-based small-molecule compound that inhibits the activity of phosphodiesterase-4 (PDE4), thereby reducing the production of TNF-alpha, IL-12, IL-23 and other pro-inflammatory cytokines that are the precursors of the inflammation associated with psoriasis.
For more information call (650) 543-7500 or visit www.anacor.com.